RTTNews | Apr 12, 2021 08:22AM EDT

08:22 Monday, April 12, 2021 (RTTNews.com) - Adamis Pharmaceuticals Corporation (ADMP) issued an update on the status of the NDA for ZIMHI high-dose naloxone injection product for the treatment of opioid overdose. The company had a Type A meeting with the FDA to review comments on the additional information provided by the company in response to the FDA's Complete Response Letter. Adamis said it believes the meeting was productive and plans to resubmit the NDA for ZIMHI to the FDA within the next 45 days.

Dennis Carlo, CEO of Adamis Pharmaceuticals, said: "We believe we obtained critical feedback from the FDA at our Type A meeting on a number of issues and also received an acknowledgement of the agency's intention to commit to a rapid review of the NDA."

Read the original article on RTTNews ( https://www.rttnews.com/3184176/adamis-to-resubmit-nda-for-zimhi-within-45-days-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved